ALI HEALTH(HK:00241) 21世纪经济报道·2025-11-27 09:14Core Viewpoint - Alibaba Health reported strong financial performance for the first half of the 2026 fiscal year, with revenue reaching RMB 16.697 billion, a year-on-year increase of 17%, and net profit growing by 64.7% to RMB 1.266 billion, indicating robust business growth and high-quality development [1] Financial Performance - Revenue for the six months ending September 30, 2025, was RMB 16.697 billion, up 17% year-on-year [1] - Gross profit reached RMB 4.184 billion, reflecting an 18.4% increase [1] - Net profit was RMB 1.266 billion, a significant rise of 64.7% [1] - Adjusted net profit stood at RMB 1.356 billion, marking a 38.7% year-on-year growth [1] Business Growth and User Engagement - Alibaba Health is one of the largest online B2C healthcare product retail platforms in China, with over 56,000 active merchants and more than 97 million SKUs [2] - The platform's annual active user count and ARPU (average revenue per user) continue to grow, with GMV (gross merchandise volume) showing stable year-on-year growth [2] - The self-operated pharmacy business generated RMB 14.38 billion in revenue, up 18.6% year-on-year, with a significant increase in active users and SKU growth of 98.8% to 1.61 million [2] Strategic Partnerships and Service Expansion - Alibaba Health has formed strategic partnerships with major pharmaceutical companies like Eli Lilly, AstraZeneca, and Bayer to enhance digital health services and expand market reach [3] - The company provides integrated online and offline healthcare services, with over 250,000 healthcare professionals offering online consultation services [3] - The self-operated chronic disease business has seen continuous growth in user numbers and ARPU [3] Digital Infrastructure and AI Development - The "Code on Trust" platform offers free traceability services to 56,000 pharmaceutical terminal enterprises, expanding into medical devices and traditional Chinese medicine [4] - Alibaba Health collaborates with over 900 leading pharmaceutical companies to provide data analysis services [4] - The company is investing in AI applications within the pharmaceutical e-commerce sector to enhance user experience and search conversion efficiency, while also exploring applications in serious medical fields [4]